Overview

• Israel medical tech firm's Q4 revenue slightly missed analyst expectations, EPS met estimates

• Company's Q4 revenue grew 6% yr/yr to $103.9 mln

• Returned $127.4 mln to shareholders through share repurchases in 2025

Outlook

• InMode expects 2026 revenue between $365 mln and $375 mln

• Company anticipates non-GAAP EPS between $1.43 and $1.48 for 2026

• InMode plans to launch two new laser-based platforms in 2026

Result Drivers

• EUROPEAN GROWTH - Record revenue in European operations contributed to Q4 growth, per CFO Yair Malca

• NORTH AMERICA STABILIZATION - Co sees early signs of stabilization in North America despite ongoing challenges, per CEO Moshe Mizrahy

• LEADERSHIP CHANGES - Refreshed sales and post-sales leadership teams in North America aim to enhance service capabilities, per President Michael Dennison

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Inmode Ltd is $16.00, about 5.8% above its February 9 closing price of $15.12

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nPn8kfg7Ja

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)